^
Association details:
| Biomarker: | MYC amplification + BCL2 amplification + TNFRSF8 expression |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Brentuximab vedotin demonstrates an objective response in a patient with refractory CD30+ primary mediastinal B-cell lymphoma
Excerpt:
We present a patient with PMBL who had increased gene copy numbers of MYC and BCL-2 along with increased protein expression of BCL-2 (c-Myc expression was about 15%-20% by immunostain)….The lymphoma, however, responded to brentuximab vedotin, a CD30-directed chemoimmunoconjugate.
DOI:
10.4103/jcrt.JCRT_696_16
